Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
769.450.1%
QQQ
717.500.2%
BTC/USD
79923.030.1032%
DIA
532.880.22%
GLD
406.530.06%
TLT
82.240.04%

Inovio Pharmaceuticals Inc

INONASDAQ
Trade with Public
Trade with Public
$1.43
0.075.15%
At close: Sep 4, 5:00 PM EST
$1.42
-0.01-0.7%
After Hours: Sep 4, 7:46 PM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

Inovio Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Inovio Pharmaceuticals (INO).

Price Target Range — 10 Quarters

Analyst Consensus — 8 Analysts

2S.Buy
4Buy
2Hold
Consensus RatingMarket Outperform# Analysts8Avg. Consensus PT$14Upside to Avg. PT+866.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 13, 2026JefferiesRoger SongUpgradeHold→Buy$2→$3
Aug 3, 2026Piper SandlerEdward TenthoffPT CutOverweight$6→$4
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Jefferies Upgrades Inovio Pharmaceuticals to Buy, Raises Price Target to $3

Jefferies analyst Roger Song upgrades Inovio Pharmaceuticals (NASDAQ:INO) from Hold to Buy and raises the price target from $1.8 to $3.
Benzinga Newsdesk

PRO
Piper Sandler Reiterates Overweight on Inovio Pharmaceuticals, Lowers Price Target to $4

Piper Sandler analyst Edward Tenthoff reiterates Inovio Pharmaceuticals (NASDAQ:INO) with a Overweight and lowers the price target from $6 to $4.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Neutral on Inovio Pharmaceuticals, Lowers Price Target to $2.5

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Inovio Pharmaceuticals (NASDAQ:INO) with a Neutral and lowers the price target from $3 to $2.5.
Benzinga Newsdesk

PRO
Piper Sandler Reiterates Overweight on Inovio Pharmaceuticals, Raises Price Target to $6

Piper Sandler analyst Edward Tenthoff reiterates Inovio Pharmaceuticals (NASDAQ:INO) with a Overweight and raises the price target from $5 to $6.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Neutral on Inovio Pharmaceuticals, Maintains $3 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Inovio Pharmaceuticals (NASDAQ:INO) with a Neutral and maintains $3 price target.
Benzinga Newsdesk

This Wingstop Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

Avi Kapoor

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved